The protein production facility is equipped to produce and purify, at cost via subcontract, HIV-1 Env proteins and antibodies as standardized in vitro reagents which can be used in HIV vaccine research. As well as HIV-1, the protein production facility also is equipped to produce HA proteins for Flu, and Spike proteins and antibodies for COVID-19. These reagents are intended to optimize clinical trial immune monitoring and facilitate Env immunogen discovery; however, the proteins are not intended for use in humans or in clinical trials.
The production of all proteins and antibodies is governed by a Quality Management plan with oversight by the Quality Assurance for Duke Vaccine Immunogenicity Program (QADVIP), Duke’s Quality Assurance Unit. All proteins and antibodies are produced following Standard Operating Procedures (SOPs) and using Good Documentation Practices. Environmental monitoring of the laboratory space, freezers, refrigerators and incubators is maintained and recorded in compliance with PPF SOPs.
2024 Inventory of all productions
Location:
Duke RADAR
27Alexandria Way
Durham, NC 27703
Contact:
Kathy Yarborough, MS
Protein Production Facility Director
919-660-1223
Email
In August 2012, the DHVI was awarded a grant by the Bill & Melinda Gates Foundation to establish a Protein Production Facility, which is directed by Kathy Yarborough, MS, with oversight from Barton Haynes, MD (Director of the Duke Human Vaccine Institute).